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Abstract
Background: Hepatitis C virus (HCV) infection and type 2 diabetes mellitus (T2DM) are two major public health
problems associated with increasing complications and mortality rates worldwide. The objective of this study is to
evaluate the prevalence of hepatitis C virus (HCV) infection in diabetic patients and to investigate the influence of
several epidemiological and clinical factors on HCV infection.
Method: A total number of one hundred and eighty diabetic patients were recruited for this study. Consented
subjects made up of 71(39.4%) males and 109(60.56%) females were recruited for the study. While one-Hundred
(100) Non-Diabetics (Controls) were also recruited for the study. Structured questionnaires were administered to the
consented participants to obtain relevant data. Sera samples were assayed for antibodies to HCV using an enzyme
linked immunosorbent assay [Inteco Diagnostic Limited]. ELISA technique.
Result: Overall prevalence of HCV infection among diabetes patients assayed was 13.3% out of which 8(11.3%) was
obtained from the male subjects compared to 16 (14.7%) seropositivity recorded among the females (P = 0.511; P >
0.05). Considering age distribution, Subjects aged 41–50 years recorded, 9 (22.5%) positivity (P = 0.238; P >
0.05).Considering educational status of subjects screened, 22 (14.9%) positivity was rescored among subjects who
have attained tertiary status of education.(P = 0.574;P > 0.05).Risk factors considered showed that, 7 (18.9%)
seropositive subject were alcoholic consumers(P value = 0.2621;P > 0.05) while 5 (8.9%) recorded history of sharing
sharp objects P = 0.2427;P > 0.05).
Conclusion: Our study shows a slightly higher prevalence of hepatitis C infection in type 2 diabetics. This call for
urgent routine screening exercise among diabetic patients for HCV infection. This study also emphasizes the need
for public enlightenment on the association between HCV infection and T2DM, to avert possible complications
among diabetic patients.
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Background
Hepatitis is the inflammation of the liver commonly
caused by a viral infection which can either be acute or
chronic, symptomatic or asymptomatic [1]. This viral in-
fection can lead to liver damage and further complica-
tions due to various causes such as heavy intake of
alcohol, toxin ingestion and certain suppressive medical
conditions [2].Hepatitis C virus (HCV) infection is a
public health concern affecting more than 170 million
people worldwide [3] [4]. HCV is a positive, single-
stranded RNA virus in the Flaviviridae family. HCV is
most efficiently transmitted through transfusion of in-
fected blood, transplantation of infected organs, mother-
to-child transmission during childbirth and interaction
with infected blood or body fluids of an infected person
[5].Most cases of Liver transplant mainly occurs as a re-
sult of HCV infection progressing to chronic infections
[6].
Hepatitis C virus (HCV) has been identified as one of
the leading causes of chronic liver disease with serious
sequel as the end stage of cirrhosis and liver cancer
[7].Hepatitis C has clearly been demonstrated to be a
precipitating factor for diabetes but only in patients with
risk factors to develop such. People with hepatitis C
virus (HCV) infection appear to be at increased risk of
developing type 2 diabetes [8].Diabetes mellitus is a
chronic disease of metabolism causing abnormal glucose
homeostasis [9].
Diabetes Mellitus, commonly referred to as diabetes is
an impairment in which the body is unable to process
glucose leading to reduction in the blood sugar level.
Diabetes is characterized by high blood glucose level(hy-
perglycemia) with problems of fat, protein, and carbohy-
drate metabolism due to the body’s inability to secrete/
act on insulin over a long period [10]. Diabetic status of
individuals are divided into two; namely Type 1 diabetes
which occurs mostly in children and adolescents and
Type 2 diabetes which occurs mostly in adults, [11].
Knobler, et al. (2000) reports an increase in DM type-
2 before the development of advanced liver cirrhosis
[12]. Previous Research found that, after excluding
chronic hepatitis C patients who received previous inter-
feron treatment, higher fibrotic stages in liver histology
and family history of DM were closely associated with
higher prevalence of DM and impaired fasting glucose in
patients with chronic hepatitis C [13].HCV infection and
type 2 diabetes mellitus are two chronic conditions
which contribute to a significant morbidity and mortal-
ity. A higher prevalence of type 2 diabetes mellitus has
been observed in the developed world (2 to 9.4%) among
patients with HCV infection than in those with other
forms of chronic hepatitis [14, 15].
Type 2 diabetes is a debilitating disease condition,
while the co-infection of type 2 diabetes and HCV has
been established to worsen this condition, hence it has
become very necessary for a screening exercise to deter-
mine the prevalence rate of HCV among diabetic pa-
tients at our location of study, so as to increase
awareness of the populace and health practitioners on
the dangers of the co-infectious status of this virus
among diabetics.
Method
Study area and population
The study was conducted at the Federal Teaching Hos-
pital Ido-Ekiti which is a tertiary health institution. The
study population comprised of randomly selected con-
firmed Diabetic patients attending the outpatient depart-
ment of the Teaching Hospital.
Ethical permit and consent
A proposal of the project was submitted to the Ethical
Review Committee of the Federal Teaching Hospital
Ido-Ekiti. Where ethical permit was sought for and ob-
tained with protocol number: ERC/2018/02/27/103B.
Inclusion and Exclusion criteria
Individuals confirmed for type 2 diabetes mellitus dia-
betes were recruited for the study. Persons who showed
no interest in the study and are not diabetic were ex-
cluded from the study.
Questionnaire and sample size
The sample size used in this research work was obtained
from One–Hundred and eighty (180) volunteering con-
firmed diabetics, while One hundred (100) samples were
also obtained from non-diabetic subjects to serve as con-
trol. All subjects recruited were informed about the
study and their consents obtained. Well-structured ques-
tionnaires developed for this study were used to collect
demographic data and other pertinent information
(Additional file).
Sample collection and processing
Three-Five [3–5] ml of blood were collected from both
diabetic (Cases) and control subjects aseptically and ac-
cording to standard procedure. Blood samples were
allowed to clot at room temperature undisturbed, there-
after Sera obtained were dispensed into a clean, dry
cryovial and stored at − 20 °C prior use. The sera were
screened for antibodies to HCV using ELISA kits (Fort-
ress Diagnostic Limited). Standard procedures were
strictly adhered during the assay process.
Data analysis
Filled questionnaires were crosschecked manually for
correct data entry. The data were analyzed using the
SPSS software package, Chi-square test was used to
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compare several Variables while the critical level for
statistical significance was set at P = 5% (0.05).
Sample processing
Sera samples obtained were screened for HCV anti-
bodies using ELISA technique according to the manu-
factures manual. Serum ALT was also assayed for,
following the procedure detailed out in the kit used.
Hepatitis C ELISA and ALT kits were stored in the re-
frigerator at 4 °C prior to use. Serum samples were ana-
lyzed at Landmark University Medical Laboratory.
Results
The total sera samples screened comprises of 71 (39.4%)
Males and 109 (60.56%) Females (Table 1).Positive sam-
ples obtained showed that, 8(4.4%) were obtained from
the Male diabetic patients while the female subjects re-
corded 16(8.9%) positivity for HCV, (Tables 2 and 3).The
age distribution of the subjects analyzed for the test
ranged from 0 to 20, 21–30, 31–40, 41–50, 51–60 and
60–100 years. Of the 180 serum samples analyzed for
HCV, 24 (13.3%) samples tested positive while 156
(86.7%) samples tested negative.
Table 4 showed the age group of individuals tested,
between 0 and 20 years, 20 (11.1%) individuals were
tested yielding 0 (0.0%) which indicates 20 (100.0%)
negative to HCV. For Subjects aged 21–30 years, 20
(11.1%) were screened out of which 2 (10.0%) showed
positivity for HCV infection with 18 (90.0%) negative to
HCV. Subjects aged 31–40 years, recorded 6(16.2%)
positivity. Subjects aged 41–50 recorded 9 (22.5%) posi-
tivity correspondingly, subjects aged 51–60 years, re-
corded 3 (12.5%) positivity to HCV infection.
Interestingly subjects aged 61–100 years, recorded 4
(10.3%) positivity.
Table 5 showed distribution of subjects based on mari-
tal status.130 (72.2%) married subjects were screened. 20
(15.4%) recorded positivity compared to 4 (9.8%) re-
corded among the single subjects.
Table 6, showed the educational background of the
subjects screened. Subjects with secondary education
status recorded 2(8.0%) positivity compared to subjects
with tertiary level of education recording 22 (14.9%)
positivity.
Table 7, showed the demographic factor of the individ-
uals was among which the traders recorded 7 (10.9%)
positivity while Civil servants screened recorded 14
(21.9%) positivity.
Table 8, Distribution of subjects screened based on
clinical risk factors of subjects with history of blood
transfusion recorded 1(6.7%) subjects with history of
previously blood donation recorded 3 (23.1%) positivity
for HCV infection. Subjects with history of care for a
hepatitis patient resulted to 6 (15.8%) positivity.
Table 9 showed distribution of subjects based on social
lifestyles, Subjects with history of alcohol consumption
recorded 7 (18.9%) positivity while subjects with tribal
marks or tattoos recorded 4 (21.1%) positivity subjects
with history of sharing unsterilized equipment yielded 5
(8.9%) positivity to HCV infection. Interestingly, subjects
with multiple sexual partners recorded 3 (42.9%) positiv-
ity to HCV infection.
Table 10, showed the distribution of subjects based on
family history; subjects with previous history of hepatitis
C virus yielded 1(0.6%) positivity; while those with family
history of diabetes tested 12 (6.7.0%) positivity. Individ-
uals with family members infected with hepatitis C virus
yielded 3 (1.7%) positivity.
Discussion
The present study found a slightly higher prevalence rate
of 13.3% among Type 2 Diabetes Mellitus (T2DM) sub-
jects, compared to the global prevalence rate of around
(3%) among the general population studied earlier. (Ta-
bles 2 and 3).The results obtained in this study compares
with the work of Nwokediuko et al., [16] in Enugu where
HCV occurrence rate among diabetic patients was found
to be 14.0%. Although, Ejele et al., [17] and Balogun
et al., [18], obtained a prevalence of 3.0% in Niger Delta
region and 0.0% in Ibadan which is lower than the result
obtained in this study. Similar study conducted among
diabetics by Ndako et al., [19] showed 11.0% prevalence
in Jos which is also lower than the result obtained in this
study, while a prevalence of 5.0% was recorded in a
study carried out among diabetes patients at UITH,
Ndako et al., [20] while 5.7% prevalence was reported
from India Demitrost et al., [21] which is lower com-
pared to the findings obtained in this study.However,
Gray et al., [22] was the first to show a higher prevalence
of HCV infection in T2DM patients with a prevalence of
8% among Asian patients. Differences in the incidence
rate of HCV results obtained from various regions
Table 1 Distribution of Hepatitis C Virus among diabetic subjects based on Gender
Gender Total number of samples examined (%) Number of Positive samples (%) Number of Negative samples (%)
Male 71(39.4) 8(4.4) 63(35.0)
Female 109(60.6) 16(8.9) 93(51.7)
Total 180(100.0) 24(13.3) 156(86.7)
Chi square (x2) = 0.433; df = 1; P value = 0.511
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Table 2 Distribution of sera samples assayed among Diabetic subjects screened
Total number of samples Number of positive samples Number of negative samples
180 24 (13.3%) 156 (86.7%)





Male 48 4(4%) 44 (44%)
Female 52 5 (5%) 47 (47%)
Total 100 9 (9%) 91 (91%)
P = 0.739; P > 0.05
Table 6 Distribution of Hepatitis C Virus According To Educational Background
Education Total number of samples examined (%) Number of Positive samples (%) Number of Negative samples (%)
Primary 6 (3.3) 0 (0.0) 6 (3.3)
Secondary 25 (13.9) 2 (1.1) 23 (12.8)
Tertiary 148 (82.2) 22 (12.2) 126 (70.0)
No Education 1 (0.6) 0 (0.0) 1 (0.6)
Total 180 (100.0) 24 (13.3) 156 (86.7)
Chi square (x2) = 1.993; df = 3; P value = 0.574
Table 5 Distribution of Hepatitis C Virus According To Marital Status
Marital Status Total number of samples examined (%) Number of Positive samples (%) Number of Negative samples (%)
Single 41 (22.8) 4 (2.2) 37 (20.6)
Married 130 (72.2) 20 (11.1) 110 (61.1)
Divorced 9 (5.0) 0 (0.0) 9 (5.0)
Total 180 (100.0) 24 (13.3) 156 (86.7)
Chi square (x2) = 2.312; df = 2; P value = 0.315
Table 4 Distribution of Hepatitis C Virus based on Age of subjects screened
Age Total number of samples examined (%) Number of Positive samples (%) Number of Negative samples (%)
0–20 20 (11.1) 0 (0.0) 20 (11.1)
21–30 20 (11.1) 2 (1.1) 18 (10.0)
31–40 37 (20.6) 6 (3.3) 31 (17.2)
41–50 40 (22.2) 9 (5.0) 31 (17.2)
51–60 24 (13.3) 3 (1.7) 21 (11.7)
60–100 39 (21.7) 4 (2.2) 35 (19.4)
Total 180 (100.0) 24 (13.3) 156 (86.6)
Chi square (x2) = 6.778; df = 5; P value = 0.238
Table 7 Distribution of Hepatitis C Virus based on Occupation of subjects screened
Occupation Total number of samples examined (%) Number Positive samples (%) Number of Negative samples (%)
Trading 64 (35.6) 7 (3.9) 57 (31.7)
Civil Servant 64 (35.6) 14 (7.8) 50 (27.8)
Industry 18 (10.0) 2 (1.1) 16 (8.9)
Student 34 (18.9) 1 (0.6) 33 (18.3)
Total 180 (100.0) 24 (13.3) 156 (86.7)
Chi square (x2) = 7.613; df = 3; P value = 0.055
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Table 8 Distribution of Hepatitis C Virus based on Clinical Risk Factors
Risk Factor Number of Positive Samples Number of Negative Samples Total Number of Samples Examined Chi-Square
Blood Transfusion
Positive 1 (0.6%) 14 (7.8%) 15 (8.3%) 0.629
Negative 23 (12.8%) 142 (78.9%) 165 (91.7%) df = 1
Total 24 (13.3%) 156 (86.7%) 180 (100.0%) P value = 0.4276
Blood Donation
Positive 3 (1.6%) 10 (5.6%) 13 (7.2%) 1.151
Negative 21 (11.7%) 146 (81.1%) 167 (92.7%) df = 1
Total 24 (13.3%) 156 (86.7%) 180 (100.0%) P value = 0.2833
History of Care for an Hepatitis C patient
Positive 6 (3.3%) 32 (17.8%) 38 (21.1%) 0.251
Negative 18 (10.0%) 124 (68.9%) 142 (78.9%) df = 1
Total 24 (13.3%) 156 (86.7%) 180 (100.0%) P value = 0.6160
Table 9 Distribution based on lifestyle-risk factors of Subjects Screened







Alcohol Consumption Positive 7 (3.9%) 30 (16.7%) 37 (20.6%) 1.257
Negative 17 (9.4%) 126 (70.0%) 143 (79.4%) df = 1
Total 24 (13.3%) 156 (86.7%) 180 (100.0%) Pvalue = 0.2621
Tribal Marks and Tattoos Positive 4 (2.2%) 15 (8.3%) 19 (10.6%) 1.095
Negative 20 (11.1%) 141 (78.4%) 161 (89.4%) df = 1
Total 24 (13.3%) 156 (86.7%) 180 (100.0%) Pvalue = 0.2953
Sharing of Unsterilized
equipment
Positive 5 (2.8%) 51 (28.3%) 56 (31.1%) 1.365
Negative 19 (10.6%) 105 (58.3%) 124 (68.9%) df = 1
Total 24 (13.4%) 156 (86.6%) 180 (100.0%) Pvalue = 0.2427
Multiple sexual partners Positive 3 (1.7%) 4 (2.2%) 7 (3.9%) 5.494
Negative 21 (11.7%) 152 (84.4%) 173 (96.1%) df = 1
Total 24 (13.4%) 156 (86.6%) 180 (100.0%) Pvalue = 0.0191
Table 10 Distribution of Hepatitis C Virus According To Family History
Risk Factor Number of Positive Samples Number of Negative Samples Total Number of Samples Examined Chi-Square
Previous Record of HCV Infection
Positive 1 (0.6%) 4 (2.2%) 5 (2.8%) 0.198
Negative 23 (12.8%) 152 (84.4%) 175 (97.2%) df = 1
Total 24 (13.4%) 156 (86.6%) 180 (100.0%) Pvalue = 0.6565
History of Diabetes by Family Members
Positive 12 (6.7%) 88 (48.9%) 100 (55.6%) 0.346
Negative 12 (6.7%) 68 (37.7%) 80 (44.4%) df = 1
Total 24 (13.4%) 156 (86.6%) 180 (100.0%) Pvalue = 0.5563
History of infection with Hepatitis by Family Members
Positive 3 (1.7%) 29 (16.1%) 32 (17.8%) 0.528
Negative 21 (11.6%) 127 (70.6%) 148 (82.2%) df = 1
Total 24 (13.3%) 156 (86.7%) 180 (100.0%) Pvalue = 0.4676
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globally depict geographical diversity. The variation in
these occurrence rates can be ascribed to exposure to
various risk factors which are capable of enhancing the
spread and transmission of this virus among individuals
[20, 21].
The Prevalence rate of HCV infection among males,
recorded 8(4.4%) while the female subjects had 14(8.9%)
Seropositivity (Fig. 1). This finding agrees with the result
obtained from a similar work by Ndako et al., [19] and
Gacche et al., [23] where the incidence of anti-HCV
among diabetic female were higher compared to the
male subjects.Increased rate of occurrence in females
could be attributed to various risk factors for HCV infec-
tion, which was quite evident from the life style and his-
tory of the individuals recruited for this study [19, 23].
A higher prevalence rate of 9(5.0%) was observed
amongst subjects aged 41–50; (Table 4; Fig. 2), this re-
sult is in accordance with the findings of Tessema et al.,
[24], where the sero-prevalence of HCV increases as age
of participants increased and it was significantly higher
in the age group of 41–50 years, which is almost similar
to the results obtained by Klevens et al., [25] which
showed a higher incidence rate among subjects aged 35–
44,which also concurs with the result obtained in this
Fig. 1 Distribution of Hepatitis C Virus according to Gender among diabetic subjects screened
Fig. 2 Distribution of Hepatitis C Virus according to Age
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study. The high seropositivity observed in older age
group could be attributed to possible differences in so-
cial practices, parenteral exposures, decline in physical
mobility and a reduced rate of medical examination
compared to younger individuals thus increasing
chances of transmission of infection, [26].
The result obtained in this study showed that subjects
with history of multiple sexual partners contributed im-
mensely to the spread of HCV;(Table 5; Fig. 3) however,
it was observed that the prevalence of HCV was higher
among married subjects (15.4%), similar study carried
out by Qureshi et al., [27] equally recorded a higher
prevalence among married subjects. This is findings
could be as a result of increased exposure to several risk
factors to this infectious agent Simo et al., [28].
Educational background of the subjects screened
showed that individuals with secondary education status
recorded 2(8.0%) positivity compared to subjects with
tertiary level of education recording 22 (14.9%) positiv-
ity, (Table 6; Fig. 4). Based on the various occupation of
subjects screened in this study, it was found that individ-
uals with trading as a profession recorded 7 (10.9%)
positivity compared to Civil servants who recorded 14
(21.9%) positivity (Fig. 5). This study did not observed
much statistical difference in the HCV distribution with
respect to Educational background and Occupation of
Fig. 3 Distribution of Hepatitis C Virus according to marital status
Fig. 4 Distribution of Hepatitis C Virus according to Educational background
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subjects screened. However, the positivity rate among
these two parameters has some important implica-
tions which warrant screening diabetic patients for
HCV as this will reduce the increased risk of HCV
infection in patients with T2DM and its transmission
rate in our institutions of learning and possible work
places, The observations recorded on Educational
background and occupation of subjects screened are
in agreement with the study of Ndako et al., [20]
conducted earlier.
Considering clinical risk factors,(Table 8; Fig. 6) it was
observed that regardless of the fact that HCV is a blood-
borne virus, the sero-prevalence among individuals that
had undergone blood transfusion or donation is of no
statistical significant difference and this agrees with the
work of Simo et al., [28].Among subjects that had his-
tory of blood donation in this study, 3 (1.7%) were found
to be positive to HCV. However, it was observed that
blood and blood products are potential sources of trans-
mission for HCV infection, Ndako et al., [19]. In the
present study, sharing personal items such as sharp ob-
jects that may be contaminated with infected blood and
tattoo practices were defined as HCV predictors. The
risk of HCV continues to be a great occupational threat.
Consequent upon which, blood transfusion was also
identified as a predictor of HCV Infection [29].
Fig. 6 Distribution of Hepatitis C Virus based on Clinical Risk Factors
Fig. 5 Distribution of Hepatitis C Virus according to occupation of Subjects screened
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High rate of positivity was equally observed in subjects
screened for alcohol consumption, sharing of
unsterilized objects also among subjects that had history
of tribal marks or tattoo. Positivity rates ranged from
3.9, 2.2 and 2.8% respectively with no statistical signifi-
cant difference.(Table 9). However, participants with
family history of diabetes recorded a sero-prevalence of
6.7% to HCV infection, this report is similar to the work
of Muller et al., [30] where the increased incidence of
HCV was closely related with family history of diabetes
mellitus. A significant difference was observed among
participants with family history of diabetes mellitus com-
pared to those without, [30, 31];(Table 10), this might be
attributed to any of multiple sexual partners, transfusion
of unscreened blood in hospitals, family history of re-
lated infections, risky behaviours such as alcohol intake
and other potential unidentified routes of transmission
which can only be discovered through advanced studies
[32].
This study found that elevated liver enzymes; espe-
cially ALT has a direct relationship with seropositivity
to HCV in the diabetic population studied, (Table 11),
showing the relevance of checking for levels of liver
transaminases as a screening test in diabetics. In a
study by Mason, [33] more than 20% of diabetes pa-
tients with consistently elevated serum aminotransfer-
ases had evidence of HCV infection. It was also
discovered that most of the anti-HCV positive dia-
betic patients presented with an abnormal liver func-
tion tests, a combination of hepatocellular and
cholestasis pattern being the predominant biochemical
alteration, Osi and Sanna., [34]. Elevation of ALT in
hepatitis C positive diabetes patients in this study is
unusually mild, with most having ALT level between
one to two times upper limit of normal.
Conclusion
The outcome of this study showed an increased risk of
HCV infection in patients with T2DM, which warrants
routine screening of diabetic subjects for HCV. Similarly,
the study adds to the limited data on the subject avail-
able in this region and will help at increasing awareness
regarding association of HCV and diabetes, which will
further help to reduce morbidity and possible mortality
associated with this comorbidity conditions in the long
run. The need for prompt enlightenment of the general
public on the threats of the co-infectious nature of HCV
and diabetes is strongly advocated. In addition, it is im-
portant that health care workers, approach the settings
of early diagnosis and management of this condition
among infected persons to avert further complications
among confirmed type 2 diabetics in the general
population.
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